Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Targeting esophageal cancer with HDL nanoparticles: an imaging study
2017-000724-10Phase 2Active
- Sponsor
- Academic Medical Center
- Start
- Jul 2017
- Modality
- Recombinant Proteins and Enzymes, Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of CER-001 in esophageal cancer, sponsored by Academic Medical Center. Primary endpoint: Tumor uptake of 89Zr-labeled CER-001. Started Jul 2017; status: active.
02
Drugs
CER-001
03
Conditions
esophageal cancer
Beyond the preview
Go deeper on 2017-000724-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-000724-10.